journal
MENU ▼
Read by QxMD icon Read
search

Journal of Thrombosis and Haemostasis: JTH

journal
https://www.readbyqxmd.com/read/28430391/analysis-of-pulmonary-embolus-size-at-the-time-of-recurrence-compared-with-presentation-a-single-centre-retrospective-study
#1
W Thomas, O Firth, M Besser, M Beveridge, T Baglin
BACKGROUND: the size of recurrent pulmonary embolus (PE) in relation to a prior event could be a factor in deciding whether to continue anticoagulation. There is no published data on this subject to help with counselling patients. OBJECTIVES: to determine whether size of a first PE predicts the size at recurrence. PATIENTS AND METHODS: retrospective cohort study of consecutive patients over 25 months, at a single tertiary centre, with recurrent PE...
April 21, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28426920/dabigatran-enhances-platelet-reactivity-and-platelet-thrombin-receptor-expression-in-patients-with-atrial-fibrillation-comment
#2
Laurent Bonello, Marc Laine, Laurence Camoin-Jau, Corinne Frere
We read with interest the article by Achilles et al. [1] in a recent issue of the Journal of Thrombosis and Haemostasis, in which the authors raised a concern regarding the safety of the oral direct thrombin inhibitor (ODTI) dabigatran. The authors aimed to investigate a potential mechanism involved in the increased risk of myocardial infarction (MI) observed in several trials of patients treated with dabigatran when compared head-to-head with patients treated with indirectly acting therapeutic anticoagulants...
April 20, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28426914/recommended-dose-of-idarucizumab-may-not-always-be-sufficient-for-sustained-reversal-of-dabigatran
#3
Alexander Simon, Hans Domanovits, Cihan Ay, Gürkan Sengölge, Jerrold H Lewy, Alexander O Spiel
Idarucizumab is a monoclonal antibody fragment designed for reversing the anticoagulant effects of dabigatran. Administration is recommended as two intravenous boluses of 2.5 g within 15 minutes of each other or as a single 5 g bolus. However, in certain situations a second dose of the drug could be necessary. We report the case of a 77-year old man, treated with dabigatran for paroxysmal atrial fibrillation. He presented at our department with acute renal failure, concomitant massive dabigatran accumulation, and subsequent acute gastrointestinal bleeding...
April 20, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28407368/association-of-body-weight-with-efficacy-and-safety-outcomes-in-phase-iii-randomized-controlled-trials-of-direct-oral-anticoagulants-a-systematic-review-and-meta-analysis
#4
Kochawan Boonyawat, Francois Caron, Ang Li, Chatree Chai-Adisaksopha, Wendy Lim, Alfonso Iorio, Renato D Lopes, David Garcia, Mark A Crowther
BACKGROUND: Concerns have arisen in direct oral anticoagulant (DOAC)-treated patients about safety and efficacy in extremes of body weight. The aims of this systematic review were to investigate the association of body weight and patient-important outcomes in patients treated with DOACs or warfarin, and to demonstrate the fixed-dose effect of DOACs. METHODS: MEDLINE, EMBASE were searched until November 2016. Phase III randomized controlled trials (RCTs) using DOACs in atrial fibrillation (AF) and acute venous thromboembolism (VTE) were included...
April 13, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28407356/risk-of-cancer-after-anticoagulation-in-patients-with-unprovoked-venous-thromboembolism-an-observational-cohort-study
#5
L Eischer, M Kammer, L Traby, P A Kyrle, S Eichinger
BACKGROUND: Patients with venous thromboembolism (VTE) are at risk of subsequent cancer diagnosis. The risk is highest during the first six months. Reports on cancer rates thereafter are controversial. We aimed to assess long-term rates and risk factors of cancer in patients with VTE. METHODS AND RESULTS: We followed patients with a first unprovoked VTE after discontinuation of anticoagulation and excluded those with long-term antithrombotic therapy or major thrombophilia...
April 13, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28397397/the-structural-basis-for-the-functional-comparability-of-factor-viii-and-the-long-acting-variant-recombinant-factor-viii-fc-fusion-protein
#6
N C Leksa, P-L Chiu, G M Bou-Assaf, C Quan, Z Liu, A B Goodman, M G Chambers, S E Tsutakawa, M Hammel, R T Peters, T Walz, J D Kulman
BACKGROUND: Fusion of the human IgG1 Fc domain to the C-terminal C2 domain of B domain-deleted (BDD) factor VIII (FVIII) results in the rFVIIIFc fusion protein that has a 1.5-fold longer half-life in humans. OBJECTIVE: To assess the structural properties of rFVIIIFc by comparing its constituent FVIII and Fc elements with their respective isolated components and evaluating their structural independence within rFVIIIFc. METHODS: rFVIIIFc and its isolated FVIII and Fc components were compared by hydrogen-deuterium exchange mass spectrometry (HDX-MS)...
April 11, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28393472/reduction-of-annexin-a5-anticoagulant-ratio-identifies-antiphospholipid-antibody-positive-patients-with-adverse-clinical-outcomes
#7
Lucia R Wolgast, Alan A Arslan, Xiao-Xuan Wu, Jessica Niakan, Vittorio Pengo, Jacob H Rand
BACKGROUND: Annexin A5 (A5) is a potent anticoagulant protein that shields anionic phospholipids from availability for coagulation reactions. Previous studies showed that antibodies from patients with antiphospholipid (aPL) syndrome (APS) interfere with A5 crystallization and anticoagulant activity. OBJECTIVE: The purpose of this study was to investigate whether reduction of the Annexin A5 Anticoagulant Ratio (A5R) assay (i.e. "A5 resistance") is associated with adverse clinical events in aPL antibody-positive patients...
April 10, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28393470/associations-of-coagulation-factors-ix-and-xi-levels-with-incident-coronary-heart-disease-and-ischemic-stroke-the-regards-study
#8
N C Olson, M Cushman, S E Judd, B M Kissela, M M Safford, G Howard, N A Zakai
BACKGROUND: Recent studies suggest the importance of coagulation factor IX (FIX) and FXI in cardiovascular disease (CVD) risk. OBJECTIVES: To determine whether basal levels of FIX or FXI antigen were associated with risk of incident coronary heart disease (CHD) or ischemic stroke. PATIENTS/METHODS: The REasons for Geographic And Racial Differences in Stroke (REGARDS) study recruited 30,239 participants across the contiguous U.S. between 2003-07...
April 10, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28393461/bleeding-risk-of-antiplatelet-drugs-compared-with-oral-anticoagulants-in-older-patients-with-atrial-fibrillation-a-systematic-review-and-meta-analysis
#9
Marc Melkonian, Witold Jarzebowski, Eric Pautas, Virginie Siguret, Joël Belmin, Carmelo Lafuente-Lafuente
BACKGROUND: The hemorrhagic risk of antiplatelet drugs in old patients could be higher as usually assumed. OBJECTIVE: To compare the bleeding risk of antiplatelet drugs and oral anticoagulants in elderly patients. METHODS: A systematic review and meta-analysis. We searched PubMed, EMBASE and the Cochrane Library up to January 2016 for randomized and non-randomized controlled trials (RCTs) and parallel cohorts comparing antiplatelet drugs and oral anticoagulants in patients 65 years or older...
April 10, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28378522/plasminogen-activator-inhibitor-1-is-associated-with-leukocyte-telomere-length-in-american-indians-findings-from-the-strong-heart-family-study
#10
Hao Peng, Fawn Yeh, Jue Lin, Lyle G Best, Shelley A Cole, Elisa T Lee, Barbara V Howard, Jinying Zhao
BACKGROUND: Plasminogen activator inhibitor-1 (PAI-1) promotes cellular aging both in vitro and in vivo. Telomere length is a marker of biological aging. OBJECTIVES: To examine the cross-sectional and longitudinal associations between plasma PAI-1 and leukocyte telomere length in a large-scale epidemiological study of American Indians. METHODS: We measured leukocyte telomere length (LTL) and plasma PAI-1 in 2,560 American Indians who were free of overt CVD and participated in the Strong Heart Family Study (SHFS) clinical exam in 2001-2003...
April 5, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28375552/predictive-performance-of-the-cha2ds2-vasc-rule-in-atrial-fibrillation-a-systematic-review-and-meta-analysis
#11
Sander van Doorn, Thomas P A Debray, Femke Kaasenbrood, Arno W Hoes, Frans H Rutten, Karel G M Moons, Geert-Jan Geersing
BACKGROUND: The CHA2DS2-VASc decision rule is widely recommended for estimating stroke risk in patients with atrial fibrillation (AF) though validation studies show ambiguous and conflicting results. OBJECTIVES: We aimed to (1) review existing studies validating CHA2DS2-VASc in AF patients not (yet) anticoagulated, 2) meta-analyze estimates of stroke risk per score, and 3) explore sources of heterogeneity across the validation studies. METHODS: We performed a systematic literature review and random effects meta-analysis of studies externally validating CHA2DS2-VASc in AF patients not on anticoagulants...
April 4, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28374963/mortality-caused-by-intracranial-bleeding-in-non-severe-hemophilia-a-patients
#12
Janneke I Loomans, Corien L Eckhardt, Sylvia E Reitter-Pfoertner, Margareta Holmström, Britta Laros van Gorkom, Frank W G Leebeek, Cristina Santoro, Saturnino Haya, Karina Meijer, Marten R Nijziel, Johanna G Van der Bom, Karin Fijnvandraat
INTRODUCTION: Non-severe hemophilia (factor VIII concentration (FVIII:C) 2-40 IU/dL) is characterized by a milder bleeding phenotype than severe hemophilia A. However, some patients with non-severe hemophilia A suffer from severe bleeding complications that may result in death. Data on bleeding-related causes of death, such as fatal intracranial bleeding in non-severe patients are scarce. Such data may provide new insight in areas of care that can be improved. AIMS: To describe mortality rates, risk factors and co-morbidities associated with fatal intracranial bleeding in non-severe hemophilia A patients...
April 4, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28374939/diagnostic-accuracy-of-igg-specific-versus-polyspecific-enzyme-linked-immunoassay-for-the-diagnosis-of-heparin-induced-thrombocytopenia-a-systematic-review-and-meta-analysis
#13
H D Husseinzadeh, P A Gimotty, A M Pishko, M Buckley, T E Warkentin, A Cuker
BACKGROUND: There is conflicting data on whether the IgG-specific or polyspecific anti-platelet factor 4/heparin (PF4/H) enzyme-linked immunosorbent assay (ELISA) is preferred for the laboratory diagnosis of heparin-induced thrombocytopenia (HIT). OBJECTIVES: To directly compare diagnostic accuracy of IgG- versus polyspecific ELISA in HIT. PATIENTS/METHODS: A systematic search yielded 9 studies comprised of 1,948 patients with suspected HIT tested by both IgG- and polyspecific ELISAs and a reference standard against which the diagnostic accuracy of the ELISAs could be measured...
April 4, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28371250/a-decision-model-to-estimate-a-risk-threshold-for-venous-thromboembolism-prophylaxis-in-hospitalized-medical-patients
#14
P Le, K A Martinez, M A Pappas, M B Rothberg
BACKGROUND: Venous thromboembolism (VTE) is a common preventable condition in medical inpatients. Thromboprophylaxis is recommended for inpatients who are not at low risk of VTE, but no specific risk threshold for prophylaxis has been defined. OBJECTIVE: To determine a threshold for prophylaxis based on risk of VTE. PATIENTS/METHODS: We constructed a decision model with a decision-tree following patients for 3 months after hospitalization, and a lifetime Markov model with 3-month cycles...
March 31, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28371181/incidence-of-intracranial-bleeds-in-new-users-of-low-dose-aspirin-a-cohort-study-using-the-health-improvement-network
#15
Lucía Cea Soriano, David Gaist, Montse Soriano-Gabarró, Luis A García Rodríguez
BACKGROUND: Low-dose aspirin protects against ischemic cardiovascular (CV) events as well as colorectal cancer (CRC). However, low-dose aspirin may be associated with a small increased risk of intracranial bleeds (ICB). OBJECTIVES: To obtain incidence rates of ICB overall and by patient subgroups among new users of low-dose aspirin. PATIENTS/METHODS: Using The Health Improvement Network (THIN) UK primary care database (2000-2012), we identified a cohort of new users of low-dose aspirin aged 40-84 years (N=199,079; mean age at start of follow-up, 63...
March 31, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28370891/adamts13-glycans-and-conformation-dependent-activity
#16
A A Nowak, H E R O'Brien, P Henne, A Doerr, K Vanhoorelbeke, M A Laffan, T A J McKinnon
BACKGROUND: ADAMTS13 activity can be regulated by its conformation where interactions between the C-terminal CUB domains and the Spacer domain maintain ADAMTS13 in a closed conformation. ADAMTS13 contains 10 N-linked glycans, with four sites present in the TSP2 through CUB domains that may contribute to its conformation. OBJECTIVES/METHODS: We hypothesized that glycosylation contributes to ADAMTS13 conformation and function. The proteolytic activity of glycan modified ADAMTS13 was assessed under static and shear stress conditions...
March 31, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28345288/single-tube-tetradecaplex-panel-of-highly-polymorphic-microsatellite-markers-1-mb-from-f8-for-simplified-preimplantation-genetic-diagnosis-of-hemophilia-a
#17
Mingjue Zhao, Min Chen, Arnold S C Tan, Felicia S H Cheah, Joyce Mathew, Peng-Cheang Wong, Samuel S Chong
BACKGROUND: It is currently not possible to perform single cell preimplantation genetic diagnosis (PGD) to directly detect the common inversion mutations of the factor VIII (F8) gene responsible for severe hemophilia A (HEMA). As such, PGD for such inversion carriers relies on indirect analysis of linked polymorphic markers. OBJECTIVES: To simplify linkage-based PGD of HEMA, we aimed to develop a panel of highly polymorphic microsatellite markers located near the F8 gene that could be simultaneously genotyped in a multiplex-PCR reaction...
March 27, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28345287/contribution-of-platelet-p2y12-receptors-to-chronic-complete-freund-s-adjuvant-induced-inflammatory-pain
#18
K Bekő, B Koványi, F Gölöncsér, G Horváth, Á Dénes, Zs Környei, B Botz, Zs Helyes, C E Müller, B Sperlágh
BACKGROUND: P2Y12 receptor antagonists are widely used in clinical practice to inhibit platelet aggregation. P2Y12 receptors are also known to regulate different forms of pain as well as local and systemic inflammation. However it is not known if platelet P2Y12 receptors contribute to these effects. OBJECTIVES: In this study, we explored the contribution of platelet P2Y12 receptors to chronic inflammatory pain in mice. METHODS: Complete Freund's adjuvant (CFA)-induced chronic inflammatory pain was induced in wild-type and P2ry12 gene-deficient mice (P2ry12-/-), and the potent, direct-acting and reversible P2Y12 receptor antagonists, PSB-0739, and cangrelor were used...
March 27, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28339167/if-you-know-you-will-also-see-population-pharmacokinetics-is-the-way-to-personalize-and-optimize-prophylaxis-in-hemophilia
#19
Erik Berntorp
The beauty of having a robust population PK model, as described here, for a specific factor concentrate is that the model is based on many PK curves (in this case n= 130) using rich sampling (in this case 9 samples taken after infusion up to 72 hours in patients aged ≥ 12 years, for some subjects even up to 96 hours). For patients below the age of 12, five samples were taken for practical reasons. If the model is robust then theoretically, This article is protected by copyright. All rights reserved.
March 24, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28339142/selective-effects-of-oral-anti-angiogenic-tyrosine-kinase-inhibitors-on-an-animal-model-of-hereditary-hemorrhagic-telangiectasia
#20
Yong Hwan Kim, Mi-Jung Kim, Se-Woon Choe, Dennis Sprecher, Young Jae Lee, S Paul Oh
BACKGROUND: Epistaxis and gastrointestinal (GI) tract hemorrhages are common symptoms of aged hereditary hemorrhagic telangiectasia (HHT) patients that result in anemia. Clinical as well as animal studies have suggested that vascular endothelial growth factor (VEGF) neutralizing antibodies lessen hemorrhage associated with adult onset arteriovenous malformations (AVMs). OBJECTIVES: The goal of this study is to evaluate potential therapeutic effects of oral delivery of four anti-angiogenic tyrosine-kinase inhibitors (TKIs) in the development of adult onset AVMs in a murine model of HHT...
March 24, 2017: Journal of Thrombosis and Haemostasis: JTH
journal
journal
20181
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"